TY  - JOUR
AU  - Pfarr, Nicole
AU  - Penzel, Roland
AU  - Endris, Volker
AU  - Lier, Clemens
AU  - Flechtenmacher, Christa
AU  - Volckmar, Anna-Lena
AU  - Kirchner, Martina
AU  - Budczies, Jan
AU  - Leichsenring, Jonas
AU  - Herpel, Esther
AU  - Noske, Aurelia
AU  - Weichert, Wilko
AU  - Schneeweiss, Andreas
AU  - Schirmacher, Peter
AU  - Sinn, Hans-Peter
AU  - Stenzinger, Albrecht
TI  - Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
JO  - Genes, chromosomes & cancer
VL  - 56
IS  - 4
SN  - 1045-2257
CY  - New York, NY
PB  - Wiley-Liss
M1  - DKFZ-2017-00970
SP  - 255 - 265
PY  - 2017
AB  - HER2-positive breast cancers are a heterogeneous group of tumors, which share amplification and overexpression of HER2. In routine diagnostics, the HER2 (ERBB2) status is currently assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Data on targeted next-generation sequencing (NGS) approaches that could be used to determine the HER2 status are sparse. Employing two breast cancer-related gene panels, we performed targeted NGS of 41 FFPE breast cancers for which full pathological work-up including ISH and IHC results was available. Selected cases were analyzed by qPCR. Of the 41 cases, the HER2 status of the 4 HER2-positive and 6 HER2-negative tumors was independently detected by our NGS approach achieving a concordance rate of 100
LB  - PUB:(DE-HGF)16
C6  - pmid:27792260
DO  - DOI:10.1002/gcc.22431
UR  - https://inrepo02.dkfz.de/record/120541
ER  -